BCL2L11 and neoplasm: The in vivo antagonizing tamoxifen-resistant MCF-7 tumor by S1g-2 illustrated it is a potential strategy for Hsp70-Bim disruption to overcome tamoxifen resistance in ER-positive breast cancer.